natgillin/translations-raw huggingface dataset:
Your doctor will monitor your blood counts and liver enzymes regularly to detect and manage these events. 
Liječnik će Vam redovito pratiti krvnu sliku i jetrene enzime da te pojave otkrije i liječi.
Name and address of the manufacturer(s) responsible for batch release medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr. 
Naziv(i) i adresa(e) proizvođača odgovornog(ih) za puštanje serije lijeka u promet medac Gesellschaft für klinische Spezialpräparate mbH Theaterstr.
Treosulfan is given in combination with fludarabine, with thiotepa (intensified regimen; FT10-14TT regimen) or without thiotepa (FT10-14 regimen). 
Treosulfan se daje u kombinaciji s fludarabinom, s tiotepom (intenzivni režim; režim FT10-14TT) ili bez nje (režim FT10-14).
Very common Pruritus 
Vrlo često pruritus
Due to its alkylating mechanism of action treosulfan is characterised as a genotoxic compound with carcinogenic potential. 
Zbog svog alkilirajućeg mehanizma djelovanja treosulfan se karakterizira kao genotoksičan spoj kancerogenog potencijala.
Trecondi may cause symptoms of the menopause (absence of menstrual periods). 
Trecondi može prouzročiti simptome menopauze (prestanak menstruacija).
An Italian group treated 60 TM patients (age range 1-37 years; including 12 adults) with the FT14 plus thiotepa regimen. 
Talijanska skupina liječila je 60 bolesnika s talasemijom major (raspon dobi 1 - 37 godina; uključujući 12 odraslih) režimom FT14 i tiotepom.
Although it cannot be proved that treosulfan was the cause, the use of clonazepam prophylaxis for children younger than 1 year might be considered. 
Iako se ne može dokazati da im je uzrok bio treosulfan, u djece mlađe od 1 godine može se uzeti u obzir profilaksa klonazepamom.
In order to prevent and treat infections, you will be given medicines, such as antibiotics, antifungals or antivirals. 
Kako bi se spriječile i liječile infekcije, primat ćete lijekove kao što su antibiotici, lijekovi protiv gljivica ili lijekovi protiv virusa.
• dry eye 
• suho oko
Therefore, infants ≤ 4 months of age should be monitored for signs of neurological adverse reactions. 
≤ 4 mjeseca potrebno pratiti zbog znakova mogućih neuroloških nuspojava.
Approximately 25-40% of the treosulfan dose is excreted unchanged with the urine within 24 hours, nearly 90% of which within the first 6 hours after administration. 
Približno 25 - 40% doze treosulfana izluči se nepromijenjeno u mokraći unutar 24 sata, gotovo 90% od toga unutar prvih 6 sati nakon primjene.
This medicine may make you infertile and it may not be possible for you to get pregnant after treatment with it. 
Ovaj lijek može prouzročiti neplodnost pa nakon liječenja možda nećete moći zatrudnjeti.
A total of 37 patients (52.9%) were younger than 12 years. 
Ukupno 37 bolesnika (52,9%) bilo je mlađe od
Men should seek advice about the possibility of sperm preservation before starting therapy. 
Muškarci moraju potražiti savjet o mogućnosti pohrane sperme prije početka terapije.
• different cancer caused by chemotherapeutic treatment (second malignancy) 
• različite vrste raka prouzročene kemoterapijom (sekundarna zloćudna bolest)
All five paediatric patients received alloHSCT for primary immunodeficiencies, i.e. diseases with an increased risk for neoplasias per se. 
Svih pet pedijatrijskih bolesnika podvrgnuto je postupku aloTKMS zbog primarnih imunodeficijencija, tj. bolesti koje same po sebi nose povećan rizik za novotvorine.
• life-threatening condition after bloodstream infection (septic shock) 
• životno opasno stanje nakon infekcije krvi (septički šok)
The latter may also be reduced by the use of a venting needle. 
Ovo posljednje može se smanjiti i primjenom igle s izlaznim ventilom.
There is not sufficient information on the use of treosulfan in children aged less than 1 month. 
Nema dovoljno informacija o primjeni treosulfana u djece mlađe od 1 mjeseca.
One of 564 adult patients (0.2%) developed a second malignancy (breast cancer). 
Od 564 odrasla bolesnika, u jednog bolesnika (0,2%) razvila se sekundarna maligna bolest (rak dojke).
Treosulfan might impair fertility in men and women. 
Treosulfan može oštetiti plodnost u muškaraca i žena.
• blocking of a vein into the liver (adults: uncommon; children and adolescents: not known) 
• začepljenje vene u jetri (odrasli: manje često; djeca i adolescenti: nepoznato)
Conventional dose calculation simply based on BSA results in a significantly higher exposure (AUC) of smaller children and infants with low BSA compared to adolescents or adults. 
Konvencionalni izračun doze, koji se temelji jednostavno na veličini tjelesne površine, rezultira značajno većom izloženošću (AUC) mlađe djece i dojenčadi male tjelesne površine nego što je to u adolescenata ili odraslih.
White crystalline powder. 
Bijeli kristaličan prah.
Rare Confusional state 
Rijetko stanje konfuzije
With a median follow-up of 36 months (range, 4-73), the 5-year overall survival probability was 93% (95% CI 83-97%). 
S medijanom praćenja od 36 mjeseci (raspon, 4 - 73), vjerojatnost 5-godišnjeg ukupnog preživljenja bila je 93% (95% CI 83 - 97%).
All patients engrafted except one, who died on day +11; the median time to neutrophil and platelet recovery was 20 days. 
U svih je bolesnika udomljavanje matičnih stanica bilo uspješno, osim u jednog bolesnika koji je preminuo na +11. dan; medijan vremena do oporavka neutrofila i trombocita bio je 20 dana.
c For testing superiority of treosulfan compared to busulfan. 
c Za testiranje superiornosti treosulfana u usporedbi s busulfanom.
No patient experienced a primary graft failure but one patient with ALL experienced a secondary graft failure. 
Ni u jednog bolesnika nije došlo do primarnog zatajenja presatka, ali je u jednog bolesnika s ALL-om došlo do sekundarnog zatajenja presatka.
Adults with malignant disease 
Odrasli s malignom bolešću
During phases of severe neutropenia (median duration of neutropenic period is 14-17.5 days in adults and 21-24 days in paediatric patients) the risk of infection is increased. 
Tijekom faza teške neutropenije (medijan trajanja razdoblja neutropenije iznosi 14 - 17,5 dana u odraslih i 21 - 24 dana u pedijatrijskih bolesnika) povećan je rizik od infekcije.
No dose accumulation with the recommended daily treatment on three consecutive days was observed. 
Uz preporučenu svakodnevnu terapiju tijekom tri uzastopna dana nije bila opažena akumulacija doze.
Treosulfan destroys the bone marrow cells and enables the transplant of new bone marrow cells which leads to the production of healthy blood cells. 
Treosulfan uništava stanice koštane srži i omogućava transplantaciju novih stanica koštane srži što dovodi do proizvodnje zdravih krvnih stanica.
For testing non-inferiority of treosulfan compared to busulfan. 
Za testiranje neinferiornosti treosulfana u usporedbi s busulfanom.
In addition, acidosis, skin toxicity, nausea, vomiting and gastritis may occur. 
Osim toga, mogu se pojaviti acidoza, kožna toksičnost, mučnina, povraćanje i gastritis.
At concentrations up to 100 µM, treosulfan has no unequivocal effect on CYP1A2, 2C9, 2C19, 2D6, or 3A4 activities in vitro. 
Pri koncentracijama do 100 µM, treosulfan nema jasan učinak na aktivnost CYP1A2, 2C9, 2C19, 2D6 ili 3A4 in vitro.
The epoxides formed alkylate nucleophilic centres of deoxyribonucleic acid (DNA) and are able to induce DNA cross-links which are considered responsible for the stem cell depleting and antineoplastic effects. 
Epoksidi oblikuju alkilatne nukleofilne centre deoksiribonukleinske kiseline (DNK) i mogu inducirati križno povezivanje lanaca DNK koje se smatra odgovornim za učinke deplecije matičnih stanica i antineoplastične učinke.
No dose adjustment is necessary for mild or moderate impairment, but treosulfan is contraindicated in patients with severe impairment (see section 4.3). 
Prilagodba doze nije potrebna u slučajevima blagog ili umjerenog oštećenja, ali je treosulfan kontraindiciran u bolesnika s teškim oštećenjem (vidjeti dio 4.3).
Adequate care and precautions should be taken in the disposal of items (syringes, needles, etc.) used to reconstitute cytotoxic medicinal products. 
Odgovarajuća pažnja i mjere opreza potrebne su kad se zbrinjava pribor (štrcaljke, igle itd.) upotrijebljen za rekonstituciju citotoksičnih lijekova.
Trecondi is a cell-killing (cytotoxic) medicine that is used to decrease the number of blood cells. 
Trecondi je lijek koji ubija stanice (citotoksičan), a koristi se za smanjenje broja krvnih stanica.
The median age of patients was 60 years (range 31-70 years); 25% of patients were older than 65 years. 
Medijan dobi bolesnika bio je 60 godina (raspon 3170 godina); 25% bolesnika bilo je starije od 65 godina.
There is limited information available on treosulfan-based conditioning (FT14 regimen ± thiotepa; see section 4.2) in adult patients with non-malignant disorders (NMD). 
Dostupne su ograničene informacije o kondicioniranju treosulfanom (režim FT14 ± tiotepa; vidjeti dio 4.2) u odraslih bolesnika s nemalignim poremećajima.
• bleeding in the eye, dry eye 
• krvarenje u oko, suho oko
Five cases of a second malignancy (myelodysplastic syndrome, acute lymphoblastic leukaemia, Ewing's sarcoma) were reported by other investigators after treosulfan-based conditioning. 
Pet slučajeva sekundarne maligne bolesti (mijelodisplastični sindrom, akutna limfoblastična leukemija, Ewingov sarkom) prijavili su drugi ispitivači nakon kondicioniranja treosulfanom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING Carton 
PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU Kutija
Very common (may affect more than 1 in 10 people) 
Vrlo često (može se pojaviti u više od 1 na 10 osoba)
Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, ATC code: L01AB02 
Farmakoterapijska skupina: antineoplastici, alkilirajući lijekovi, ATK oznaka: L01AB02
In the absence of haematopoietic stem cell transplantation, the recommended dose of treosulfan would constitute an overdose. 
Bez transplantacije krvotvornih matičnih stanica, preporučena doza treosulfana smatrala bi se predoziranjem.
Pregnant personnel should be excluded from handling cytotoxics. 
Trudnice među osobljem treba isključiti iz rukovanja citotoksičnim materijalom.
• heart not pumping enough blood for the body's needs (heart failure), heart attack, fluid in the sac around the heart (pericardial effusion) 
• srce ne pumpa dovoljno krvi za potrebe tijela (srčano zatajenje), srčani udar, tekućina u srčanoj ovojnici (perikardijalni izljev)
The freedom from transplant-related mortality until day +100 after HSCT (primary endpoint) is 98.6% (90% CI 93.4-99.7%) because one of the 70 patients died due to transplantation/treatment-related cause until day +100 after HSCT. 
Odsutnost smrtnosti povezane s transplantatom do +100. dana nakon TKMS-a (primarna mjera ishoda) iznosi 98,6% (90% CI 93,499,7%) jer je jedan od 70 bolesnika umro zbog uzroka povezanog s transplantacijom/liječenjem do +100. dana nakon TKMS-a.
Transplant-related mortality at 12 months is 2.9% (90% CI 0.9 - 8.9%). 
Smrtnost povezana s transplantatom u 12. mjesecu bila je 2,9% (90% CI 0,9 - 8,9%).
Not known Febrile neutropenia 
Nepoznato febrilna neutropenija
The most frequent adverse reactions were cardiac arrhythmias, e.g. atrial fibrillation (1.2%), sinus tachycardia (0.9%), supraventricular tachycardia (0.4%), and ventricular extrasystole (0.4%). 
Najčešće nuspojave bile su srčane aritmije, npr. fibrilacija atrija (1,2%), sinusna tahikardija (0,9%), supraventrikularna tahikardija (0,4%) i ventrikularna ekstrasistola (0,4%).
Secondary malignancies are well-established complications in long-term survivors after alloHSCT. 
Sekundarne maligne bolesti dobro su poznate komplikacije u osoba s dugim preživljenjem nakon aloTKMS-a.
• leakage of fluid from the capillaries (small blood vessels), high blood pressure, low blood pressure 
• istjecanje tekućine iz kapilara (male krvne žile), visok krvni tlak, nizak krvni tlak
The reconstituted solution contains 50 mg treosulfan per mL and appears as a clear colourless solution. 
Rekonstituirana otopina sadrži 50 mg treosulfana po ml i izgledom je bistra bezbojna otopina.
• bloodstream infection (sepsis) 
• infekcija krvi (sepsa)
P value 
P vrijednost
No pharmacokinetic studies with treosulfan were done in patients with severe renal or hepatic impairment, because such patients are generally excluded from alloHSCT. 
Farmakokinetička ispitivanja s treosulfanom nisu provedena u bolesnika s teškim oštećenjem bubrežne ili jetrene funkcije jer su takvi bolesnici uglavnom isključeni iz aloTKMS-a.
The most frequent adverse reactions reported were nausea (39.5%), stomatitis (36%), vomiting (22.5%), diarrhoea (15.6%), and abdominal pain (10.4%). 
Najčešće prijavljene nuspojave bile su mučnina (39,5%), stomatitis (36%), povraćanje (22,5%), proljev (15,6%) i bol u abdomenu (10,4%).
In juvenile rat toxicity studies treosulfan induced slight retardation of physical development and a slightly delayed time-point of vaginal opening in females. 
U ispitivanjima toksičnosti u juvenilnih štakora treosulfan je izazvao blago usporenje tjelesnog razvoja i neznatno odgodio vrijeme vaginalnog otvaranja u ženki.
This medicine is used in combination with fludarabine. 
Ovaj se lijek daje u kombinaciji s fludarabinom.
If you are a man treated with this medicine, you should not father a child during and up to 6 months after treatment. 
Ako ste muškarac i liječite se ovim lijekom, ne smijete začeti dijete tijekom liječenja i do 6 mjeseci nakon toga.
Treosulfan has moderate influence on the ability to drive and use machines. 
Treosulfan umjereno utječe na sposobnost upravljanja vozilima i rada sa strojevima.
The cumulative incidence of relapse/progression is 15.7% (90% CI 8.6-22.9%) at month +12. 
Kumulativna incidencija recidiva/progresije bila je 15,7% (90% CI 8,6 - 22,9%) u +12. mjesecu.
Trecondi is used as a treatment before blood stem cell transplantation in adults with cancer and non-cancerous disorders, and in adolescents and children older than one month with cancer. 
Trecondi se primjenjuje kao terapija prije transplantacije krvnih matičnih stanica u odraslih s rakom i drugim bolestima koje nisu zloćudne te adolescenata i djece starije od jednog mjeseca s rakom.
Published data concerning treatment of mice and rats with L-diepoxibutane (the alkylating transformation product of treosulfan) revealed impairment of fertility, uterine-ovarian and sperm development. 
Objavljeni podaci koji se odnose na liječenje miševa i štakora L-diepoksibutanom (alkilirajući produkt transformacije treosulfana) otkrili su oštećenje plodnosti, razvoja maternice i jajnika te sperme.
Maximum plasma levels (mean ± SD) in adult patients after a 2-hour intravenous infusion of 10, 12, or 14 g/m² treosulfan were 306 ± 94 µg/mL, 461 ± 102 µg/mL, and 494 ± 126 µg/mL, respectively. 
Maksimalne razine u plazmi (srednja vrijednost ± SD) u odraslih bolesnika nakon 2-satne intravenske infuzije treosulfana od 10, 12 ili 14 g/m² bile su 306 ± 94 µg/ml, 461 ± 102 µg/ml odnosno 494 ± 126 µg/ml.
• decrease in the oxygen supply to parts of the body (hypoxia) 
• smanjen dotok kisika u neke dijelove tijela (hipoksija)
• decreased counts of white blood cells with fever (febrile neutropenia) 
• smanjen broj bijelih krvnih stanica s vrućicom (febrilna neutropenija)
The lowest frequencies of these adverse reactions were seen with the dose regimen of 10 g/m² per day, day -4 to -2 (20.4%, 30.3%, 13.1%, 5.0%, and 5.5% respectively). 
Najniže učestalosti tih nuspojava opažene su pri režimu doziranja od 10 g/m² na dan od -4. do -2. dana (20,4%; 30,3%; 13,1%; 5,0% odnosno 5,5%).
• Treosulfan should be administered before fludarabine; 
• Treosulfan je potrebno primijeniti prije fludarabina.
There have been isolated reports of seizures in infants (≤ 4 months of age) with primary immunodeficiencies after conditioning treatment with treosulfan in combination with fludarabine or cyclophosphamide. 
Bilo je izoliranih prijava napadaja u dojenčadi (u dobi ≤ 4 mjeseca) s primarnim imunodeficijencijama nakon terapije kondicioniranja treosulfanom u kombinaciji s fludarabinom ili ciklofosfamidom.
Not known Alkalosis 
Nepoznato alkaloza
Pathogens included bacteria (e.g. Staphylococcus, Enterococcus, Corynebacterium), viruses (e.g. cytomegalovirus [CMV], Epstein-Barr virus [EBV], herpes) as well as fungi (e.g. candida). 
Patogeni su uključivali bakterije (npr. Staphylococcus, Enterococcus, Corynebacterium), viruse (npr. citomegalovirus [CMV], Epstein-Barrov virus [EBV], herpes) te gljivice (npr. kandidu).
Prophylactic or empiric anti-infective treatment (bacterial, viral, fungal) should therefore be considered. 
Stoga je potrebno razmotriti potrebu profilaktičke ili empirijske terapije protiv infekcija (bakterijskih, virusnih, gljivičnih).
About 25-40% of treosulfan is excreted in urine; however, an influence of renal function on renal clearance of treosulfan was not observed. 
Oko 25 - 40% treosulfana izluči se u mokraći; međutim, utjecaj bubrežne funkcije na bubrežni klirens treosulfana nije opažen.
Treosulfan is used to prepare patients for bone marrow transplant (haematopoietic stem cell transplantation). 
Treosulfan se koristi kako bi se bolesnike pripremilo za transplantaciju koštane srži (transplantacija krvotvornih matičnih stanica).
Breast-feeding should be discontinued during treatment with treosulfan. 
Dojenje treba prekinuti za vrijeme liječenja treosulfanom.
• problems in the nerves of the arms or legs with symptoms such as numbness, reduced or increased sensitivity, tingling, burning pain (peripheral sensory neuropathy) 
• teškoće sa živcima ruku ili nogu sa simptomima kao što su utrnulost, smanjena ili povećana osjetljivost, peckanje, žareći bol (periferna senzorna neuropatija)
The efficacy and safety of treosulfan-based conditioning was evaluated in 70 patients with acute lymphoblastic leukaemia (ALL), AML, MDS, or juvenile myelomonocytic leukaemia (JMML) who received a conditioning regimen with treosulfan and fludarabine with (n = 65) or without (n = 5) thiotepa (see section 4.2). 
Djelotvornost i sigurnost kondicioniranja treosulfanom procijenjene su u 70 bolesnika s akutnom limfoblastičnom leukemijom (ALL), AML-om, MDS-om ili juvenilnom mijelomonocitnom leukemijom (JMML) kojima je primijenjen režim kondicioniranja treosulfanom i fludarabinom s tiotepom (n = 65) ili bez nje (n = 5) (vidjeti dio 4.2).
The active substance is treosulfan. 
Djelatna tvar je treosulfan.
Therefore, nappies should be changed frequently during 6-8 hours after each dose of this medicine. 
Stoga je tijekom 6 - 8 sati nakon svake doze ovog lijeka potrebno često mijenjati pelene.
As known for other alkylating conditioning agents treosulfan can cause ovarian suppression and amenorrhoea with menopausal symptoms in pre-menopausal women. 
Kao što je poznato za druga alkilirajuća sredstva za kondicioniranje, treosulfan može prouzročiti supresiju jajnika i amenoreju sa simptomima menopauze u žena u predmenopauzi.
Remove the treosulfan powder carefully from the inner surface of the vial by shaking. 
Protresanjem pažljivo ukonite prah treosulfana s unutarnje površine bočice.
Women of childbearing potential/Contraception in males and females Both sexually active men and women of childbearing potential have to use effective contraception during and up to 6 months after treatment. 
Spolno aktivni muškarci i žene reproduktivne dobi moraju primjenjivati učinkovitu kontracepciju tijekom liječenja te do 6 mjeseci nakon toga.
• bruising, low blood pressure 
• modrice, nizak krvni tlak
Treosulfan is for intravenous use as a two-hour infusion. 
Treosulfan je za intravensku primjenu kao dvosatna infuzija.
Profound myelosuppression/pancytopenia is the desired therapeutic effect of conditioning therapy and occurs in all patients. 
Duboka mijelosupresija/pancitopenija željeni je učinak terapije kondicioniranja i događa se u svih bolesnika.
Dermatitis diaper may occur in small children because of excretion of treosulfan in the urine. 
Pelenski dermatitis može se razviti u male djece zbog izlučivanja treosulfana u mokraći.
The European Medicines Agency has deferred the obligation to submit the results of a study with treosulfan-based conditioning in paediatric patients with non-malignant diseases (see section 4.2 for information on paediatric use). 
Europska agencija za lijekove odgodila je obvezu podnošenja rezultata ispitivanja kondicioniranja treosulfanom u pedijatrijskoj populaciji s nemalignim bolestima (vidjeti dio 4.2 za informacije o pedijatrijskoj primjeni).
Under physiological conditions (pH 7.4, temperature 37 °C), the pharmacologically inactive treosulfan is converted spontaneously (non-enzymatically) into the active monoepoxide intermediate (S,S-EBDM = (2S,3S)-1,2-epoxybutane-3,4-diol-4-methanesulfonate) and finally to L-diepoxibutane (S,S-DEB = (2S,3S)-1,2:3,4-diepoxybutane). 
U fiziološkim uvjetima (pH 7,4, temperatura 37 °C), farmakološki neaktivan treosulfan konvertira se spontano (ne-enzimski) u aktivni monoepoksidni intermedijer (S,S-EBDM = (2S,3S)-1,2-epoksibutan-3,4-diol-4-metansulfonat) i konačno u L-diepoksibutan (S,S-DEB = (2S,3S)-1,2:3,4-diepoksibutan).
There are no data from the use of treosulfan in pregnant women. 
Nema podataka o primjeni treosulfana u trudnica.
Do not store the reconstituted solution in a refrigerator (2 °C - 8 °C) as this might cause precipitation. 
Rekonstituiranu otopinu nemojte čuvati u hladnjaku (2 °C - 8 °C) jer to može prouzročiti taloženje.
Published literature data report on gonadotoxicity of treosulfan in pre-pubertal and pubertal male and female mice. 
Objavljeni literaturni podaci ukazuju na gonadotoksičnost treosulfana u mužjaka i ženki miševa prije puberteta i u pubertetu.
Not known Septic shockc 
Nepoznato septički šokc
This medicine is used in combination with fludarabine and in most cases also with thiotepa. 
Ovaj lijek se daje u kombinaciji s fludarabinom te u većini slučajeva i s tiotepom.
Trecondi contains the active substance treosulfan, which belongs to a group of medicines called alkylating agents. 
Trecondi sadrži djelatnu tvar treosulfan, koja spada u skupinu lijekova pod nazivom alkilirajući lijekovi.
• increased blood level of a liver enzyme (gamma-glutamyl transferase) 
• povišena razina jetrenog enzima u krvi (gama glutamiltransferaze)
Since inflammation of the oral mucosa is a common side effect of this medicine, you should pay attention to adequate oral hygiene. 
Budući da je upala sluznice usne šupljine česta nuspojava ovoga lijeka, morate posvetiti pažnju odgovarajućoj higijeni usne šupljine.
• less acid than normal in the blood (alkalosis), abnormal blood level of electrolytes, decreased blood level of magnesium 
• manje kiseline u krvi nego što je to normalno (alkaloza), poremećene razine elektrolita u krvi, snižena razina magnezija u krvi
It is given by drip (infusion) into a vein over 2 hours for 3 days before blood stem cell infusion. 
Daje se kapanjem (infuzijom) u venu u trajanju od 2 sata 3 dana prije infuzije matičnih krvnih stanica.
How much treosulfan contributes to their occurrence is unknown. 
U kojoj mjeri treosulfan pridonosi njihovoj pojavi nije poznato.
The median (25%/75% percentiles) duration of neutropenia was 21 (16, 26) days in paediatric patients with malignant diseases and 24 (17, 26) days in patients with non-malignant disorders. 
Medijan (25%/75% percentila) trajanja neutropenije iznosio je 21 (16, 26) dana u pedijatrijskih bolesnika s malignim bolestima i 24 (17, 26) dana u bolesnika s nemalignim poremećajima.
Treosulfan is a prodrug that is spontaneously converted under physiological conditions (pH 7.4; 37 °C) into a monoepoxide intermediate and L-diepoxybutane with a half-life of 2.2 hours. 
Treosulfan je prolijek koji se u fiziološkim uvjetima (pH 7,4; 37 °C) spontano konvertira u monoepoksidni intermedijer i L-diepoksibutan s poluvijekom od 2,2 sata.
Common Decreased appetite 
Često smanjen apetit
1 vial 5 vials 
1 bočica 5 bočica
Gastrointestinal disorders were observed in 357 patients (63.3%). 
Poremećaji probavnog sustava opaženi su u 357 bolesnika (63,3%).
The activity of treosulfan is due to the spontaneous conversion into a mono-epoxide intermediate and L-diepoxybutan (see section 5.2). 
Za aktivnost treosulfana odgovorna je spontana konverzija u monoepoksidni intermedijer i L-diepoksibutan (vidjeti dio 5.2).